… The objective of this study is to examine the efficacy of erlotinib and gefitinib with respect
to epidermal growth factor (EGF) and cetuximab response in head and neck cancer cell lines. …

… Laboratory and clinical data suggest that these tumors still depend on signaling through the
… of a trial combining erlotinib and cetuximab in patients with acquired resistance to erlotinib. …

… erlotinib 150 mg oral daily and cetuximab 250 mg/m 2 iv weekly. In summary, erlotinib and
cetuximab … five of 20 patients with non–small cell lung cancer (25%), including individuals with …

… heterogeneity and this is further complicated by cancer stem cells (CSC) shifting between …
the effects of Cetuximab and Erlotinib on the cell sub-populations in HNSCC cell lines. …

… a phase I study combining erlotinib, cetuximab, and … tumors (excluding colorectal and
non-small cell lung cancers) were analyzed for safety, toxicity profile, and response. Anti-tumor …

… The aim of this study was to evaluate the incidence of cutaneous reactions to cetuximab
and erlotinib, and to describe their clinical features and therapeutic management. …

… cetuximab and erlotinib on the growth of colon cancer cells in … data showed synergy between
cetuximab and erlotinib, we … cancer—the Dual Targeting of EGFR Using Cetuximab and …

… To further investigate the growth delay effect of cetuximab-resistant tumors by erlotinib we …
tumor samples. We first measured cell proliferation (Ki67) in tumors treated with erlotinib (T1, …

… Erlotinib and Cetuximab on T790M and L858R mutation lung cancer cells lines (H1975),
in the primary NSCLC cells … -resistant EGFR mutations human tumor xenograft model (H1975). …

… cohort would validate cetuximab at a dose of 250 mg/m 2 weekly plus erlotinib at 150 mg
daily as … where either cetuximab or erlotinib is known to be active, including colorectal cancer, …